1. European Group for Blood and Marrow Transplantation Risk Score Predicts the Outcome of Patients with Acute Leukemia Receiving Single Umbilical Cord Blood Transplantation 
Xiaoyu Zhu, Lulu Huang, Changcheng Zheng, Baolin Tang, Huilan Liu, Liangquan Geng, Juan Tong, Lei Zhang, Xuhan Zhang, Wen Yao, Kaidi Song, Xingbing Wang, Kaiyang Ding, Zimin Sun 
Biology of Blood and Marrow Transplantation 
Volume 23, Issue 12, Pages (December 2017)
DOI: /j.bbmt
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
(A) The projected 3-year OS was 65.0% (95% CI, 57.6% to 71.4%) and the projected 3-year LFS was 59.8% (95% CI, 52.1% to 66.7%). (B) The cumulative incidences of 3-year NRM and 3 year-relapse rate were 19.5% (95% CI, 14.2% to 25.5%) and 20.3% (95% CI, 14.6% to 26.7%), respectively.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Evaluation of outcomes based on the EBMT risk score. (A) and (B) Projected OS of patients with EBMT risk scores of 1, 2, 3, and 4 to 6 were 81.7%, 72.2%, 58.1%, and 43.8%, respectively, after sUCBT (P = .00363), and the LFS of the patients with scores of 1, 2, 3, and 4 to 6 were 75.9%, 62.6%, 53.2%, and 44.3%, respectively, after sUCBT (P = .00823). (C) and (D) Cumulative incidences of 3-year NRM were 7.3%, 19.0%, 23.1%, and 31.7% (P = .0539) and of the 3-year relapse rate were 15.3%, 18.3%, 23.8%, and 23.9% (P = .408) for scores of 1, 2, 3, and 4 to 6, respectively.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
After pooling patients into 4 scoring bins (0, 1, 2, and 3 to 5), the sUCBT-EBMT risk score is predictive for OS, LFS, NRM, and relapse rates. (A) and (B) Projected 3-year OS and LFS of patients with sUCBT-EMBT risk scores of 0, 1, 2, and 3 to 5 were 90.0%, 78.4%, 71.2%, and 28.5% (P < .0001) and 80.0%, 72.6%, 63.5%, and 26.2% (P < .0001), respectively, after sUCBT. (C) and (D) Cumulative incidences of NRM and relapse rate of patients with scores of 0, 1, 2, and 3 to 5 were .0%, 10.0%, 15.4%, and 46.3% (P < .0001) and 11.1%, 17.4%, 21.1%, and 27.2% (P = .33), respectively, after sUCBT.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions